The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy
Meisam Saberi,1 Zahra Ramazani,1 Homeira Rashidi,2 Alihossein Saberi3 1Department of Medical Chemistry, School of Pharmacy, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 2Diabetic Research Center, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 3Department of Medical Ge...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-06-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-effect-of-cyp2c9-genotype-variants-in-type-2-diabetes-on-the-pharm-peer-reviewed-article-VHRM |
| _version_ | 1811210238908432384 |
|---|---|
| author | Saberi M Ramazani Z Rashidi H Saberi A |
| author_facet | Saberi M Ramazani Z Rashidi H Saberi A |
| author_sort | Saberi M |
| collection | DOAJ |
| description | Meisam Saberi,1 Zahra Ramazani,1 Homeira Rashidi,2 Alihossein Saberi3 1Department of Medical Chemistry, School of Pharmacy, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 2Diabetic Research Center, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 3Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranCorrespondence: Alihossein SaberiDepartment of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranTel +98-9161133488Fax +98-6133332036Email saberi-a@ajums.ac.irAim: Type 2 diabetes (T2D), as a major cause of morbidity and mortality, is predicted to have a prevalence of 629 million by 2045. As diabetic patients show considerable inter-individual variation in response to antidiabetic treatment, this study aimed to investigate the gene polymorphism of cytochrome P450 as well as the effectiveness and safety of glibenclamide and gliclazide for different genotypes of CYP2C9. Besides, the chronic side effects of T2D including retinal microvasculature complications or retinopathy and renal dysfunction due to nephropathy in different genotypes were considered.Patients and Methods: The participants including 80 T2D patients treated with glibenclamide or gliclazide were recruited from university hospitals of Ahvaz Jundishpur University of Medical Sciences, Ahvaz, in the southwest of Iran. Blood samples were collected from the patients at 2.5h after the morning dose of glibenclamide and 12h after the last dose of gliclazide. Genotyping from the extracted DNA was, then, performed using PCR-RFLP. The plasma level of glibenclamide and gliclazide was, in turn, measured by the reverse-phase high-pressure liquid chromatography.Results: The results showed that the wild-type allele, i.e., CYP2C9*1, occurred in the highest frequency (0.8), while the frequency rates of the mutant allele, i.e., CYP2C9*2 and CYP2C9*3, were 0.15 and 0.05, respectively. Moreover, no significant association was found between any of the genotypes as well as the clinical and biochemical characteristics of the patients. The findings also showed that the plasma level of sulfonylureas (i.e., glibenclamide and gliclazide) was the highest in the patients with the CYP2C9*3 allele. It was also found that 75.9% of the patients with variant genotypes had experienced hypoglycemia events. Furthermore, in the absence of wild type allele, a significant increase was observed in retinopathy (p=0.039) and nephropathy (p=0.05).Conclusion: The findings can provide guidelines for the optimal management of the treatment protocols with sulfonylurea intended to control the T2D complications.Keywords: CYP2C9, glibenclamide, gliclazide, retinopathy, nephropathy |
| first_indexed | 2024-04-12T04:52:26Z |
| format | Article |
| id | doaj.art-5cd72ba377c54983abb1e3b51ebaaab7 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-04-12T04:52:26Z |
| publishDate | 2020-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-5cd72ba377c54983abb1e3b51ebaaab72022-12-22T03:47:16ZengDove Medical PressVascular Health and Risk Management1178-20482020-06-01Volume 1624124854642The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and NephropathySaberi MRamazani ZRashidi HSaberi AMeisam Saberi,1 Zahra Ramazani,1 Homeira Rashidi,2 Alihossein Saberi3 1Department of Medical Chemistry, School of Pharmacy, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 2Diabetic Research Center, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 3Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranCorrespondence: Alihossein SaberiDepartment of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IranTel +98-9161133488Fax +98-6133332036Email saberi-a@ajums.ac.irAim: Type 2 diabetes (T2D), as a major cause of morbidity and mortality, is predicted to have a prevalence of 629 million by 2045. As diabetic patients show considerable inter-individual variation in response to antidiabetic treatment, this study aimed to investigate the gene polymorphism of cytochrome P450 as well as the effectiveness and safety of glibenclamide and gliclazide for different genotypes of CYP2C9. Besides, the chronic side effects of T2D including retinal microvasculature complications or retinopathy and renal dysfunction due to nephropathy in different genotypes were considered.Patients and Methods: The participants including 80 T2D patients treated with glibenclamide or gliclazide were recruited from university hospitals of Ahvaz Jundishpur University of Medical Sciences, Ahvaz, in the southwest of Iran. Blood samples were collected from the patients at 2.5h after the morning dose of glibenclamide and 12h after the last dose of gliclazide. Genotyping from the extracted DNA was, then, performed using PCR-RFLP. The plasma level of glibenclamide and gliclazide was, in turn, measured by the reverse-phase high-pressure liquid chromatography.Results: The results showed that the wild-type allele, i.e., CYP2C9*1, occurred in the highest frequency (0.8), while the frequency rates of the mutant allele, i.e., CYP2C9*2 and CYP2C9*3, were 0.15 and 0.05, respectively. Moreover, no significant association was found between any of the genotypes as well as the clinical and biochemical characteristics of the patients. The findings also showed that the plasma level of sulfonylureas (i.e., glibenclamide and gliclazide) was the highest in the patients with the CYP2C9*3 allele. It was also found that 75.9% of the patients with variant genotypes had experienced hypoglycemia events. Furthermore, in the absence of wild type allele, a significant increase was observed in retinopathy (p=0.039) and nephropathy (p=0.05).Conclusion: The findings can provide guidelines for the optimal management of the treatment protocols with sulfonylurea intended to control the T2D complications.Keywords: CYP2C9, glibenclamide, gliclazide, retinopathy, nephropathyhttps://www.dovepress.com/the-effect-of-cyp2c9-genotype-variants-in-type-2-diabetes-on-the-pharm-peer-reviewed-article-VHRMcyp2c9glibenclamidegliclazideretinopathynephropathy |
| spellingShingle | Saberi M Ramazani Z Rashidi H Saberi A The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy Vascular Health and Risk Management cyp2c9 glibenclamide gliclazide retinopathy nephropathy |
| title | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy |
| title_full | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy |
| title_fullStr | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy |
| title_full_unstemmed | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy |
| title_short | The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy |
| title_sort | effect of cyp2c9 genotype variants in type 2 diabetes on the pharmacological effectiveness of sulfonylureas diabetic retinopathy and nephropathy |
| topic | cyp2c9 glibenclamide gliclazide retinopathy nephropathy |
| url | https://www.dovepress.com/the-effect-of-cyp2c9-genotype-variants-in-type-2-diabetes-on-the-pharm-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT saberim theeffectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT ramazaniz theeffectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT rashidih theeffectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT saberia theeffectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT saberim effectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT ramazaniz effectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT rashidih effectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy AT saberia effectofcyp2c9genotypevariantsintype2diabetesonthepharmacologicaleffectivenessofsulfonylureasdiabeticretinopathyandnephropathy |